Prevention for Whom?
It reshapes epidemiology at the level of what we count, how we model, and what we consider a “cause.”
First, it shifts epidemiology from a pathogen-centered science to a syndemic science. Instead of treating HIV or STIs as isolated outcomes, epidemiology must model co-occurring conditions—substance use, housing instability, mental health, incarceration—as interacting drivers. This aligns with Farmer’s structural violence: incidence and prevalence are not just biological distributions, but patterned outcomes of inequality. The “exposure” is no longer just behavior; it is structure.
Second, it transforms surveillance into a biopolitical system. In a Foucauldian sense, telehealth, electronic records, pharmacy data, and real-time testing produce continuous streams of population-level data. Epidemiology becomes less about periodic measurement and more about ongoing monitoring of adherence (PrEP uptake, viral suppression), risk categorization, and intervention targeting. The field moves from observing populations to actively governing them through data.
Third, it complicates causal inference. A Marxist and Derridean reading would push epidemiology to interrogate how pharmaceutical access, insurance status, and market dynamics function as upstream determinants. For example, PrEP effectiveness in trials does not translate evenly at the population level because access is stratified. Traditional models risk overstating “behavioral” causality while underestimating structural constraints. The result is a need for multi-level, policy-sensitive models that treat access itself as a causal mechanism.
Fourth, it redefines intervention effects. Telehealth and biomedical tools deterritorialize care (in a Deleuze and Guattari sense), allowing interventions to operate outside clinics. Epidemiology must now measure not just individual outcomes, but how interventions move through networks—digital platforms, community organizations, pharmacies—and how they are reassembled across contexts. Effectiveness becomes relational, not fixed.
Finally, it introduces new biases and inequities into data itself. Telehealth-dependent surveillance can systematically miss populations without stable internet, phones, or trust in institutions. This produces data shadows—groups that are epidemiologically invisible but highly burdened. What looks like declining incidence in datasets may partly reflect who is counted, not just who is infected.
In synthesis: epidemiology is no longer just the study of disease distribution—it becomes the study of how biomedical technologies, data systems, and social structures co-produce patterns of health and illness. The field must integrate critical theory not as abstraction, but as a way to correctly specify models, interpret disparities, and design interventions that address both biology and power.
Anthropologically, the U.S. response to syndemic HIV/STIs—through telehealth, PrEP, ART, DoxyPEP, and long-acting injectables—operates as a single socio-technical formation rather than separate interventions. It is an assemblage that simultaneously expands survival and reorganizes power. Biomedical tools reduce transmission and mortality, while telehealth extends reach into stigmatized, rural, and marginalized populations. Yet this expansion is not neutral—it is structured by capital, governance, and inequality.
From a Marxist perspective, these innovations represent a contradiction: the capacity to end HIV transmission increasingly exists, but access is mediated through pharmaceutical ownership, patents, insurance markets, and fragmented public systems. Life-saving drugs become commodities, and adherence becomes a condition of participation in healthcare capitalism. Survival is thus both enabled and priced.
A Foucauldian lens shows how this system governs bodies through risk management. Telehealth, routine testing, adherence monitoring, and prevention protocols produce a subject who is continuously visible, measurable, and responsible. Care becomes a form of discipline—not coercive in a traditional sense, but embedded in norms of “good” biomedical citizenship.
Through Derrida, this system destabilizes itself: telehealth is both liberation and surveillance; pharmaceuticals are both care and commodification. The promise of “ending HIV” depends on excluding the very structural conditions—racism, housing instability, criminalization, digital divides—that sustain the syndemic.
A Deleuzian-Guattarian reading clarifies that HIV/STI care is an assemblage of flows—drugs, data, bodies, institutions—constantly deterritorializing (e.g., telehealth disrupting clinic space) and reterritorializing (e.g., insurance, billing, and pharmaceutical control reasserting structure). Innovation moves faster than equity, and the system continually reorganizes itself around profit and governance.
Finally, through Paul Farmer’s structural violence, the key insight is that biomedical revolution alone cannot resolve a syndemic. HIV/STIs persist not because tools are lacking, but because access is stratified. The uneven rollout of telehealth and pharmaceuticals reflects deeper inequalities in housing, income, race, and healthcare infrastructure.
In synthesis, telehealth and biomedical interventions are not simply solutions—they are sites where care, capital, and control converge. Their revolutionary potential depends on whether they remain commodified technologies or are embedded within a broader restructuring of social conditions that produce vulnerability in the first place.
Comments
Post a Comment